142 related articles for article (PubMed ID: 35129278)
1. Feasibility and effectiveness of HCV viraemia testing at harm reduction sites in Georgia: A prospective three-arm study.
Shilton S; Markby J; Japaridze M; Chihota V; Shadaker S; Gvinjilia L; Tsereteli M; Alkhazashvili M; Butsashvili M; Stvilia K; Ruiz RJ; Asatiani A; Adamia E; Easterbrook P; Khonelidze I; Gamkrelidze A
Liver Int; 2022 Apr; 42(4):775-786. PubMed ID: 35129278
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse.
Lamoury FMJ; Soker A; Martinez D; Hajarizadeh B; Cunningham EB; Cunningham P; Bruggmann P; Foster GR; Dalgard O; Backmund M; Conway B; Robaeys G; Swan T; Cloherty G; Marks P; Grebely J; Dore GJ; Applegate TL
J Clin Virol; 2017 Jul; 92():32-38. PubMed ID: 28521211
[TBL] [Abstract][Full Text] [Related]
3. Clinical utility of HCV core antigen detection and quantification using serum samples and dried blood spots in people who inject drugs in Dar-es-Salaam, Tanzania.
Mohamed Z; Mbwambo J; Shimakawa Y; Poiteau L; Chevaliez S; Pawlotsky JM; Rwegasha J; Bhagani S; Taylor-Robinson SD; Makani J; Thursz MR; Lemoine M
J Int AIDS Soc; 2017 Sep; 20(1):21856. PubMed ID: 28953324
[TBL] [Abstract][Full Text] [Related]
4. Progress and challenges of a pioneering hepatitis C elimination program in the country of Georgia.
Averhoff F; Shadaker S; Gamkrelidze A; Kuchuloria T; Gvinjilia L; Getia V; Sergeenko D; Butsashvili M; Tsertsvadze T; Sharvadze L; Zarkua J; Skaggs B; Nasrullah M
J Hepatol; 2020 Apr; 72(4):680-687. PubMed ID: 31811882
[TBL] [Abstract][Full Text] [Related]
5. Confirmation of HCV viremia using HCV RNA and core antigen testing on dried blood spot in HIV infected peoples who inject drugs in Vietnam.
Nguyen TT; Lemee V; Bollore K; Vu HV; Lacombe K; Thi XLT; Luong QA; Dubos C; Plantier JC; Thi HD; Laureillard D; Lemoine M; Tuaillon E
BMC Infect Dis; 2018 Dec; 18(1):622. PubMed ID: 30514229
[TBL] [Abstract][Full Text] [Related]
6. Point-of-care HCV RNA testing improves hepatitis C testing rates and allows rapid treatment initiation among people who inject drugs attending a medically supervised injecting facility.
MacIsaac MB; Whitton B; Anderson J; Cogger S; Vella-Horne D; Penn M; Weeks A; Elmore K; Pemberton D; Winter RJ; Papaluca T; Howell J; Hellard M; Stoové M; Wilson D; Pedrana A; Doyle JS; Clark N; Holmes JA; Thompson AJ
Int J Drug Policy; 2024 Mar; 125():104317. PubMed ID: 38281385
[TBL] [Abstract][Full Text] [Related]
7. Impact of hepatitis C virus point-of-care RNA viral load testing compared with laboratory-based testing on uptake of RNA testing and treatment, and turnaround times: a systematic review and meta-analysis.
Trickey A; Fajardo E; Alemu D; Artenie AA; Easterbrook P
Lancet Gastroenterol Hepatol; 2023 Mar; 8(3):253-270. PubMed ID: 36706775
[TBL] [Abstract][Full Text] [Related]
8. Utility of hepatitis C virus core antigen testing for diagnosis and treatment monitoring in HCV infection: A study from India.
Kumbhar N; Ramachandran K; Kumar G; Rao Pasupuleti SS; Sharma MK; Gupta E
Indian J Med Microbiol; 2021; 39(4):462-466. PubMed ID: 34294505
[TBL] [Abstract][Full Text] [Related]
9. Reliability of hepatitis C virus core antigen assay for detection of viremia in HCV genotypes 1, 2, 3, and 4 infected blood donors: a collaborative study between Japan, Egypt, and Uzbekistan.
Agha S; Tanaka Y; Saudy N; Kurbanov F; Abo-Zeid M; El-Malky M; Khalaf M; Ohta N; Yoshizawa H; Mizokami M
J Med Virol; 2004 Jun; 73(2):216-22. PubMed ID: 15122795
[TBL] [Abstract][Full Text] [Related]
10. Performance of Hepatitis C Virus (HCV) Core Antigen Assay in the Diagnosis of Recently Acquired HCV Infection among High-Risk Populations.
Sun HY; Liu WD; Wang CW; Wei YJ; Lin KY; Huang YS; Su LH; Chen YT; Liu WC; Su YC; Chen YW; Chuang YC; Lu PL; Hung CC; Yu ML
Microbiol Spectr; 2022 Jun; 10(3):e0034522. PubMed ID: 35579445
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the Xpert HCV VL Fingerstick point-of-care assay and dried blood spot HCV-RNA testing as simplified diagnostic strategies among people who inject drugs in Catalonia, Spain.
Saludes V; Antuori A; Lazarus JV; Folch C; González-Gómez S; González N; Ibáñez N; Colom J; Matas L; Casabona J; Martró E
Int J Drug Policy; 2020 Jun; 80():102734. PubMed ID: 32470849
[TBL] [Abstract][Full Text] [Related]
12. Utility of a one-step screening and diagnosis strategy for viremic HCV infection among people who inject drugs in Catalonia.
Saludes V; Antuori A; Folch C; González N; Ibáñez N; Majó X; Colom J; Matas L; Casabona J; Martró E;
Int J Drug Policy; 2019 Dec; 74():236-245. PubMed ID: 31706159
[TBL] [Abstract][Full Text] [Related]
13. Barriers of linkage to HCV viremia testing among people who inject drugs in Georgia.
Butsashvili M; Abzianidze T; Kamkamidze G; Gulbiani L; Gvinjilia L; Kuchuloria T; Tskhomelidze I; Gogia M; Tsereteli M; Miollany V; Kikvidze T; Shadaker S; Nasrullah M; Averhoff F
Subst Abuse Treat Prev Policy; 2022 Mar; 17(1):23. PubMed ID: 35346265
[TBL] [Abstract][Full Text] [Related]
14. Acceptability and preferences of point-of-care finger-stick whole-blood and venepuncture hepatitis C virus testing among people who inject drugs in Australia.
Bajis S; Maher L; Treloar C; Hajarizadeh B; Lamoury FMJ; Mowat Y; Schulz M; Marshall AD; Cunningham EB; Cock V; Ezard N; Gorton C; Hayllar J; Smith J; Whelan M; Martinello M; Applegate TL; Dore GJ; Grebely J;
Int J Drug Policy; 2018 Nov; 61():23-30. PubMed ID: 30388566
[TBL] [Abstract][Full Text] [Related]
15. Performance of ORTHO HCV core antigen and trak-C assays for detection of viraemia in pre-seroconversion plasma and whole blood donors.
Tobler LH; Stramer SL; Lee SR; Baggett D; Wright D; Hirschkorn D; Walsh I; Busch MP
Vox Sang; 2005 Nov; 89(4):201-7. PubMed ID: 16262752
[TBL] [Abstract][Full Text] [Related]
16. Clinical utility of hepatitis C virus core antigen (HCVcAg) assay to identify active HCV infection in hemodialysis and renal transplant patients.
Ponnuvel S; Fletcher GJ; Anantharam R; Varughese S; David VG; Abraham P
PLoS One; 2021; 16(4):e0250263. PubMed ID: 33886631
[TBL] [Abstract][Full Text] [Related]
17. The correlation between hepatitis C core antigen and hepatitis C virus RNA levels with respect to human immunodeficiency virus status, hepatitis C virus genotype and interferon-lambda-4 polymorphism.
Thong VD; Akkarathamrongsin S; Avihingsanon A; Theamboonlers A; Poovorawan Y; Tangkijvanich P
Intervirology; 2015; 58(2):73-9. PubMed ID: 25677196
[TBL] [Abstract][Full Text] [Related]
18. Performance of HCV core antigen and PCR testing in a predominantly genotype 3 population.
Naveed A; Khalid A; Janjua N; Cloherty GA; Akhter S
J Viral Hepat; 2024 Jun; 31(6):320-323. PubMed ID: 38483043
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis C virus core antigen: A potential alternative to HCV RNA testing among persons with substance use disorders.
Talal AH; Chen Y; Zeremski M; Zavala R; Sylvester C; Kuhns M; Brown LS; Markatou M; Cloherty GA
J Subst Abuse Treat; 2017 Jul; 78():37-42. PubMed ID: 28554601
[TBL] [Abstract][Full Text] [Related]
20. Performance of a conventional enzyme immunoassay for hepatitis C virus core antigen in the early phases of hepatitis C infection.
Aoyagi K; Iida K; Ohue C; Matsunaga Y; Tanaka E; Kiyosawa K; Yagi S
Clin Lab; 2001; 47(3-4):119-27. PubMed ID: 11294574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
